124 research outputs found

    New Variable Compliance Method for Estimating In-Situ Stress and Leak-Off from DFIT Data

    Full text link
    It is shown that using Carter leak-off is an oversimplification that leads to significant errors in the interpretation of DFIT data. Most importantly, this article reveals that previous methods of estimating minimum in-situ stress often lead to significant over or underestimates. Based on our modeling and simulation results, we propose a much more accurate and reliable method to estimate the minimum in-situ stress and fracture pressure dependent leak-off rate

    Periodontitis as a causative agent for systemic disease of pancreas

    Get PDF
    In recent years it has been studied that periodontal diseases have a strong correlation with systemic health. The purpose of the present study is to correlate the periodontitis with the pancreatic health. Two hundred sixty subjects were selected for this study and divided in control and chronic periodontitis. Amylase, lipase, glucose, cholesterol, sodium, potassium and calcium level were measured in serum of all subjects. Significant changes were observed in amylase, glucose, cholesterol and calcium levels in periodontitis subjects

    Re-examining interpretations of non-ideal behavior during diagnostic fracture injection tests

    Get PDF
    AbstractDiagnostic fracture injection tests (DFITs) are performed in low permeability formations to estimate the minimum principal stress, formation pressure, permeability, and other parameters. G-function derivative plots are used for diagnosing fracture closure and “non-ideal” reservoir processes. In this study, we use a discrete fracture network hydraulic fracturing simulator to investigate non-ideal DFIT mechanisms. The simulator fully couples fluid flow with the stresses induced by fracture deformation. DFITs are simulated for six different scenarios: a single hydraulic fracture, multiple fracture strands, opening of transverse fractures, near-wellbore complexity, far-field complexity, and height recession. The results indicate that pressure transient behavior commonly ascribed to “fracture height recession,” “closure of transverse fractures,” and “fracture tip extension” are likely to be misinterpreted by conventional techniques. In previous studies, we found that a curving upward G×dP/dG plot is caused by changing fracture stiffness after closure and that the closure pressure is best picked when G×dP/dG begins to deviate upward. In contrast, the commonly used “tangent” method can significantly underestimate the minimum principal stress. The results of this study confirm those prior results. The results suggest that in most cases, it should be possible to use pump-in/flowback tests to confirm estimates of the minimum principal stress. However, if a flow bottleneck occurs at the wellbore due to near-wellbore complexity, the pump-in/flowback test may be uninterpretable

    In situ

    Full text link

    Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial

    Get PDF
    Background: Patent foramen ovale (PFO) is a contributor to embolic stroke of undetermined source (ESUS). Subgroup analyses from previous studies suggest that anticoagulation could reduce recurrent stroke compared with antiplatelet therapy. We hypothesised that anticoagulant treatment with rivaroxaban, an oral factor Xa inhibitor, would reduce the risk of recurrent ischaemic stroke compared with aspirin among patients with PFO enrolled in the NAVIGATE ESUS trial. Methods: NAVIGATE ESUS was a double-blinded, randomised, phase 3 trial done at 459 centres in 31 countries that assessed the efficacy and safety of rivaroxaban versus aspirin for secondary stroke prevention in patients with ESUS. For this prespecified subgroup analysis, cohorts with and without PFO were defined on the basis of transthoracic echocardiography (TTE) and transoesophageal echocardiography (TOE). The primary efficacy outcome was time to recurrent ischaemic stroke between treatment groups. The primary safety outcome was major bleeding, according to the criteria of the International Society of Thrombosis and Haemostasis. The primary analyses were based on the intention-to-treat population. Additionally, we did a systematic review and random-effects meta-analysis of studies in which patients with cryptogenic stroke and PFO were randomly assigned to receive anticoagulant or antiplatelet therapy. Findings: Between Dec 23, 2014, and Sept 20, 2017, 7213 participants were enrolled and assigned to receive rivaroxaban (n=3609) or aspirin (n=3604). Patients were followed up for a mean of 11 months because of early trial termination. PFO was reported as present in 534 (7·4%) patients on the basis of either TTE or TOE. Patients with PFO assigned to receive aspirin had a recurrent ischaemic stroke rate of 4·8 events per 100 person-years compared with 2·6 events per 100 person-years in those treated with rivaroxaban. Among patients with known PFO, there was insufficient evidence to support a difference in risk of recurrent ischaemic stroke between rivaroxaban and aspirin (hazard ratio [HR] 0·54; 95% CI 0·22–1·36), and the risk was similar for those without known PFO (1·06; 0·84–1·33; pinteraction=0·18). The risks of major bleeding with rivaroxaban versus aspirin were similar in patients with PFO detected (HR 2·05; 95% CI 0·51–8·18) and in those without PFO detected (HR 2·82; 95% CI 1·69–4·70; pinteraction=0·68). The random-effects meta-analysis combined data from NAVIGATE ESUS with data from two previous trials (PICSS and CLOSE) and yielded a summary odds ratio of 0·48 (95% CI 0·24–0·96; p=0·04) for ischaemic stroke in favour of anticoagulation, without evidence of heterogeneity. Interpretation: Among patients with ESUS who have PFO, anticoagulation might reduce the risk of recurrent stroke by about half, although substantial imprecision remains. Dedicated trials of anticoagulation versus antiplatelet therapy or PFO closure, or both, are warranted. Funding: Bayer and Janssen
    • …
    corecore